Trial Profile
12-Week, Open-Label, Multi-Center, Prospective Study Evaluating the Effect of Individualizing Starting Doses of Rosuvastatin According to Baseline LDL-Cholesterol Levels on Achieving Cholesterol Targets in Type 2 Diabetic Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms ADAPT
- Sponsors AstraZeneca
- 01 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Sep 2008 New trial record.